Tag: ovarian cancer

1. Breastfeeding was found to be significantly associated with decrease risk of invasive ovarian cancer, including high-grade serous and endometroid cancer. Evidence Rating: 2 (Good) Ovarian cancer is a significant contributor to female mortality, with 5-year survival following diagnosis being less than 50%. Prevention is critical for reducing disease mortality, but...
Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial 1. Patients receiving landiolol were more likely to achieve target heart rates of 60-94 following sepsis-related tachyarrhythmia and had significantly reduced incidence of new onset arrhythmia Evidence Rating: 1...
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer. 2. In this phase 3 trial, patients with newly diagnosed advanced ovarian cancer who received niraparib had a significantly longer progression-free survival than those who received...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage ovarian cancer,...
1. Niraparib, a PARP (polyadenosine diphosphate ADP-ribose polymerase) inhibitor, has been associated with an increase in progression-free survival among patients with recurrent ovarian cancer. 2. In this phase 3 trial, patients with newly diagnosed advanced ovarian cancer who received niraparib had a significantly longer progression-free survival than those who received...
1. This phase 3 trial of olaparib plus bevacizumab showed a significant progression-free survival benefit for ovarian cancer maintenance therapy. 2. The progression-free survival benefit was greater in patients with BRCA-positive and homologous recombination deficiency (HRD) positive tumors. Evidence Rating Level: 1 (Excellent) Study Rundown: Due to the late diagnosis of advanced-stage...
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive disease. Evidence Rating Level: 2 (Good) Although previous investigations have indicated that the immune system plays an important role in ovarian cancer control, results from trials thus far on single-agent immune...
1. Nivolumab and bevacizumab combination therapy appears to be efficacious in relapsed epithelial ovarian cancer, especially in patients with platinum-sensitive disease. Evidence Rating Level: 2 (Good) Although previous investigations have indicated that the immune system plays an important role in ovarian cancer control, results from trials thus far on single-agent immune...
Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial 1. Adjuvant FOLFOX improves disease-free survival in patients with pathologic Stage II or III rectal cancer after upfront surgery and preoperative chemoradiotherapy, but is associated with a higher rate of adverse events. Evidence...
1. Pelvic and paraaortic lymphadenectomy in advanced ovarian cancer patients provided no overall or progression-free survival benefits compared to patients not undergoing lymphadenectomy. 2. Serious postoperative complications, including postoperative death, occurred at greater rates in patients undergoing systematic lymphadenectomy. Evidence Rating Level: 1 (Excellent)     Study Rundown: Patients with advanced ovarian cancer generally...